These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18773845)

  • 21. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
    Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CALGB 90202.
    Clin Adv Hematol Oncol; 2006 Dec; 4(12):897-8. PubMed ID: 17235272
    [No Abstract]   [Full Text] [Related]  

  • 24. [Bisphosphonates in oncology].
    Kurth AA; Heidenreich A; Diel I
    Orthopade; 2007 Feb; 36(2):131-5. PubMed ID: 17252255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
    Miki T; Okihara K
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
    [No Abstract]   [Full Text] [Related]  

  • 26. Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention?
    Tombal B
    Eur Urol; 2015 Mar; 67(3):492-4. PubMed ID: 24666840
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of bisphosphonates in cancer treatment.
    Coleman R
    Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
    Serefoglu EC; Balbay MD
    Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
    Sridharan S; Steigler A; Spry NA; Joseph D; Lamb DS; Matthews JH; Atkinson C; Tai KH; Duchesne G; Christie D; Attia J; Holliday EG; Denham JW
    Radiother Oncol; 2016 Oct; 121(1):98-102. PubMed ID: 27528117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
    Moseshvili E; Joseph DJ; Spry NA; Cohen RJ; Abreu A; Kautto A; Denham JW
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Winquist E; Berry S
    J Natl Cancer Inst; 2004 Aug; 96(15):1183; author reply 1183-1184. PubMed ID: 15292391
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
    Bankhead C
    J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of bisphosphonates in prostate cancer.
    Khan MA
    BJU Int; 2003 Jul; 92(1):152. PubMed ID: 12823405
    [No Abstract]   [Full Text] [Related]  

  • 37. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
    Hoskin P; Sundar S; Reczko K; Forsyth S; Mithal N; Sizer B; Bloomfield D; Upadhyay S; Wilson P; Kirkwood A; Stratford M; Jitlal M; Hackshaw A
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26242893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of bisphosphonates in the treatment of prostate cancer.
    Parker CC
    BJU Int; 2005 May; 95(7):935-8. PubMed ID: 15839907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.